The Omnigraft dermal regeneration matrix from Integra Lifesciences is an advanced bilayer dermal regeneration matrix that treats diabetic foot ulcers. It is the only FDA-approved product that can regenerate native dermal tissue, according to the company. The patch has a built-in silicone layer that serves as a temporary epidermal layer and provides immediate coverage for wound protection. It can be removed between two and three weeks. Under the silicone layer is a collagen/chrondroitin-6-sulfate matrix that acts as a dermal replacement layer. It is a bioengineered scaffold that promotes dermal regeneration and is designed with a controlled porosity and degradation rate.The Omnigraft dermal regeneration matrix is designed to be used for treating partial and full thickness neuropathic diabetic foot ulcers that are more than six weeks old with no capsule, tendon or bone showing.
Thanks for pointing out. Our sister publication MassDevice actually reported in September that some researchers found an “unusually high” rate of early failure related to the Attune knee systems tibial components. http://www.massdevice.com/report-depuys-attune-knee-seeing-unusually-high-rate-early-failure/ I added a mention of the news to the slide about Attune. Perhaps the Prix Galien USA Committee was too soon to highlight Attune as innovative?
Balint Frankosays
I’d like to know how did you measure “innovative” properties of a medical device? What was the standard for measurement? Your list, looks very subjective and misleading.
Chris Newmarkersays
Thanks for the comment, Balint. The list includes the 11 medical technology nominees for the 11th Annual Prix Galien USA Award from the Galien Foundation. They said the nominees were chosen by a judging committee of “13 renowned leaders from the biomedical industry and academia, including four Nobel Laureates.” So I guess if there was any subjectivity on their part, it was Nobel Laureate–level subjectivity.
Karinsays
Agree with Franko – for example, a hyaluronic acid lip filler is really not new in any way.
Chris Newmarkersays
Thanks for the comment, Karin. So you think the Prix Galien USA Awards aren’t highlighting innovation the way they should?
I am not sure about this…. some contradictory experience reported…
https://www.odtmag.com/contents/view_breaking-news/2017-09-18/first-us-lawsuit-filed-against-depuy-synthes-for-attune-knee-replacement-failure/
Thanks for pointing out. Our sister publication MassDevice actually reported in September that some researchers found an “unusually high” rate of early failure related to the Attune knee systems tibial components. http://www.massdevice.com/report-depuys-attune-knee-seeing-unusually-high-rate-early-failure/ I added a mention of the news to the slide about Attune. Perhaps the Prix Galien USA Committee was too soon to highlight Attune as innovative?
I’d like to know how did you measure “innovative” properties of a medical device? What was the standard for measurement? Your list, looks very subjective and misleading.
Thanks for the comment, Balint. The list includes the 11 medical technology nominees for the 11th Annual Prix Galien USA Award from the Galien Foundation. They said the nominees were chosen by a judging committee of “13 renowned leaders from the biomedical industry and academia, including four Nobel Laureates.” So I guess if there was any subjectivity on their part, it was Nobel Laureate–level subjectivity.
Agree with Franko – for example, a hyaluronic acid lip filler is really not new in any way.
Thanks for the comment, Karin. So you think the Prix Galien USA Awards aren’t highlighting innovation the way they should?
These 11 innovations are great for the medical field.